Compare GEF & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEF | NAMS |
|---|---|---|
| Founded | 1877 | 2019 |
| Country | United States | Netherlands |
| Employees | 12000 | 100 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | N/A | N/A |
| Metric | GEF | NAMS |
|---|---|---|
| Price | $66.60 | $31.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $73.33 | $46.75 |
| AVG Volume (30 Days) | 186.8K | ★ 852.4K |
| Earning Date | 01-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.85 | $25.64 |
| Revenue Next Year | $1.83 | $530.85 |
| P/E Ratio | $4.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $50.23 | $14.06 |
| 52 Week High | $77.14 | $42.00 |
| Indicator | GEF | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 50.14 |
| Support Level | $64.44 | $29.73 |
| Resistance Level | $68.14 | $31.72 |
| Average True Range (ATR) | 1.76 | 1.69 |
| MACD | 0.04 | 0.19 |
| Stochastic Oscillator | 59.22 | 79.25 |
Greif Inc is a producer of industrial packaging products and services with manufacturing facilities located in many countries. It offers a comprehensive line of rigid industrial packaging products, such as steel, fiber, and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and remanufactured and reconditioned industrial containers, and services, such as container life cycle management, blending, filling, logistics, warehousing, and other packaging services. The company operates in three reportable business segments including Global Industrial Packaging, Paper Packaging and Services, and Land Management. It operates in USA, Europe, Middle East, Africa and Asia and Other Americas.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.